MAA
HRTX icon

Managed Account Advisors’s Heron Therapeutics HRTX Stock Holding History

Managed Account Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$4K Buy
+135
New +$2.54K ﹤0.01% 2950

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Managed Account Advisors's HRTX Position: Q2 2015 in Review

Managed Account Advisors opened a new position in Heron Therapeutics (HRTX) in Q2 2015: 135 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #2950 among its holdings.

88 funds tracked by Wall St. Rank hold HRTX as of Q2 2015.

  • Managed Account Advisors held 135 shares of Heron Therapeutics worth $4K as of Q2 2015.
  • Heron Therapeutics was a new Managed Account Advisors position in Q2 2015.
  • Heron Therapeutics made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2950 holding.
  • 88 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.